Emily B. Heikamp
Molecular Biology · 2011
A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Molecular Biology — 35 citations into it; #17,579 of 17,773 by trust here, #11,207 by citations
Whom Emily B. Heikamp trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Emily B. Heikamp overall
Papers from Emily B. Heikamp's perspective
Ordered by how strongly the researchers Emily B. Heikamp trusts endorse each paper. Same corpus, a different order for every researcher.
- Upstream and downstream of mTOR. (Genes & Development)
- Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. (Molecules and Cells)
- mTOR and cancer: insights into a complex relationship (Nature Reviews. Cancer)
- Defining the role of mTOR in cancer. (Cancer Cell)
- TOR, a central controller of cell growth. (Cell)
- The AKT–mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells (Journal of Experimental Medicine)
- mTOR signaling at a glance (Journal of Cell Science)
- Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. (Genes & Development)
- The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1 (Science)
- T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR (Proceedings of the National Academy of Sciences of the United States of America)
Their papers
- The mammalian Target of Rapamycin (mTOR) regulates T helper cell differentiation through the selective activation of mTORC1 and mTORC2 signaling (2011) — 935 citations
- Regulation of Immune Responses by mTOR (2011) — 821 citations